Loading patent…
AssigneesMemorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai
InventorsPeter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
Estimating the term…
Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.
A chimeric Newcastle disease virus (NDV), comprising a packaged genome which encodes an agonist of a co-stimulatory receptor of an immune cell or an antagonist of an inhibitory receptor of an immune cell, wherein the agonist or antagonist is expressed by the virus.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating cancer, comprising administering to a subject in need thereof an NDV and an agonist of a co-stimulatory receptor of an immune cell or an antagonist of an inhibitory receptor of an immune cell.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.